Sugi Predict

Sugi Predict / Compounds / SCHEMBL1605161

SCHEMBL1605161

SCHEMBL1605161

O=C(O)c1cccc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)c1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 13/20 0.64
▸ CNR1 P21554 5/20 0.64
▸ CNR2 P34972 4/20 0.64
▸ HTR2B P41595 1/20 0.61
▸ KMT2A Q03164 12/20 0.61
▸ HTT P42858 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ MAPK1 P28482 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604029 0.92 CNR1 (0.64) MEN1CNR1CNR2HTR2BKMT2A
SCHEMBL1604665 0.91 MEN1 (0.61) MEN1CNR1CNR2HTR2BKMT2A
SCHEMBL1604944 0.91 MEN1 (0.61) MEN1CNR1CNR2HTR2BKMT2A
SCHEMBL1604180 0.90 MEN1 (0.60) MEN1CNR1CNR2HTR2BKMT2A
SCHEMBL1604955 0.87 HTR2B (0.70) MEN1CNR1HTR2BKMT2AHTT
SCHEMBL1604148 0.85 HTR2B (0.70) MEN1HTR2BKMT2AHTTSMN1; SMN2
SCHEMBL13060028 0.85 MEN1 (0.66) MEN1HTR2BKMT2AHTTSMN1; SMN2
SCHEMBL13905660 0.85 HTR2B (0.62) MEN1HTR2BKMT2AHTTSMN1; SMN2
SCHEMBL1604829 0.83 MEN1 (0.61) MEN1HTR2BKMT2AHTTSMN1; SMN2
SCHEMBL1604942 0.83 HTR2B (0.72) MEN1HTR2BKMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 — — EP claimed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 — — EP claimed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 — — WO claimed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 — — US claimed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 — — EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 — — US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 — — US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 — — US disclosed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 — — EP disclosed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 — — WO disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 — — US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis HTR2B, HTR3B, HTR1B MEN1 4310/4885CNR1 164/4885CNR2 70/4885
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A MEN1 2389/4885CNR1 111/4885CNR2 85/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885CNR1 296/4885CNR2 118/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885CNR1 296/4885CNR2 118/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A MEN1 2784/4885CNR1 146/4885CNR2 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.